Knight Therapeutics Stock Investor Sentiment

KHTRF Stock  USD 3.73  0.02  0.53%   
Roughly 62% of Knight Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Knight Therapeutics pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Knight Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Knight Therapeutics stock news signals to limit their universe of possible portfolio assets.
Knight Therapeutics pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Knight daily returns and investor perception about the current price of Knight Therapeutics as well as its diversification or hedging effects on your existing portfolios.
  
over a year ago at news.google.com         
Executive Chairman of Knight Therapeutics Jonathan Goodman Buys More Stock - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Asha Therapeutics Selected as a BLUE KNIGHT Company by ... - BioSpace
Google News at Macroaxis
over a year ago at news.google.com         
2023 Cutaneous Leishmaniasis Drugs Market Investment Outlook Grab Sustainable Opportunities - Benzin...
Google News at Macroaxis
over a year ago at news.google.com         
JPMorgan Elevates Hofmann, Carpenter to Run North America MA - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA for IBS-C at GH...
Google News at Macroaxis
over a year ago at news.google.com         
60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conferenc...
Google News at Macroaxis
over a year ago at news.google.com         
Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money R...
Google News at Macroaxis
over a year ago at news.google.com         
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Ta...
Google News at Macroaxis
over a year ago at news.google.com         
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Pl...
Google News at Macroaxis
over a year ago at news.google.com         
Kessler Topaz Meltzer Check, LLP Notification Deadline Reminder for Bausch Health Companies Inc. Inv...
Google News at Macroaxis
over a year ago at news.google.com         
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Intercontinental Exchange, Black Knight and the Federal Trade Commission Jointly Agree to Dismiss Fe...
Google News at Macroaxis
over a year ago at news.google.com         
Notice of Knight Therapeutics Second Quarter 2023 Results Conference Call - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Gu...
Google News at Macroaxis
over a year ago at news.google.com         
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Knight Therapeutics that are available to investors today. That information is available publicly through Knight media outlets and privately through word of mouth or via Knight internal channels. However, regardless of the origin, that massive amount of Knight data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Knight Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Knight Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Knight Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Knight Therapeutics alpha.

Knight Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Knight Pink Sheet analysis

When running Knight Therapeutics' price analysis, check to measure Knight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Knight Therapeutics is operating at the current time. Most of Knight Therapeutics' value examination focuses on studying past and present price action to predict the probability of Knight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Knight Therapeutics' price. Additionally, you may evaluate how the addition of Knight Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance